

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EXTRAWELL PHARMACEUTICAL HOLDINGS LIMITED

精優藥業控股有限公司*

(Incorporated in Bermuda with limited liability)

(Stock Code: 00858)

UPDATE ON POSITIVE PROFIT ALERT

This announcement is made by Extrawell Pharmaceutical Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcement of the Company dated 15 June 2015 (the “**Announcement**”). Capitalized terms used herein shall bear the same meanings as defined in the Announcement, unless otherwise stated.

The Board wishes to update the Shareholders and potential investors that the Company is in the process of finalizing its annual results for the year ended 31 March 2015. According to the Board’s latest assessment and based on the information currently available to it; including the Management Accounts and a draft valuation report in respect of the fair value of the Group’s investment in an associate, the Company expects further increase in the consolidated profit attributable to equity holders of the Company for the year ended 31 March 2015, which is primarily attributable to, among other things, the non-cash and non-recurring gain on disposal of the Group’s 51% equity interest in Smart Ascent Limited, including gain on the fair value of the Group’s retained interest in Smart Ascent Limited and fair value changes in the Group’s investment in convertible bonds in aggregate of about HK\$550 million.

The Company is still in the process of finalizing the annual results of the Group for the year ended 31 March 2015. The information as set out above is only based on the latest assessment by the Board on the information currently available to it, including the Management Accounts, which have not been finalized and are subject to audit or further review by the Company's auditors. The annual results of the Company for the year ended 31 March 2015 are expected to be published before the end of June 2015.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Extrawell Pharmaceutical Holdings Limited
Xie Yi
Chairman

Hong Kong, 24 June 2015

As at the date of this announcement, the executive directors are Dr. Xie Yi, Dr. Lou Yi, Mr. Cheng Yong, Ms. Wong Sau Kuen and Mr. Liu Kwok Wah and the independent non-executive directors are Mr. Fang Lin Hu, Mr. Xue Jing Lun and Ms. Jin Song.

** For identification purpose only*